Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.68 |
| ▸ | CA2 | P00918 | 7/20 | 0.68 |
| ▸ | CA9 | Q16790 | 7/20 | 0.68 |
| ▸ | CA12 | O43570 | 6/20 | 0.68 |
| ▸ | CA1 | P00915 | 6/20 | 0.68 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CA3 | P07451 | 1/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.68 |
| ▸ | CA4 | P22748 | 1/20 | 0.68 |
| ▸ | CA6 | P23280 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | PDE4A | P27815 | 1/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891512 | 0.91 | PTGS2 (0.70) | PTGS2CA2CA9CA12CA1 | |
| SCHEMBL4884123 | 0.89 | PTGS2 (0.64) | PTGS2CA2CA9CA12CA1 | |
| SCHEMBL4809281 | 0.89 | PTGS2 (0.70) | PTGS2CA2CA9CA12CA1 | |
| SCHEMBL6169802 | 0.87 | PTGS2 (0.61) | PTGS2CA2CA9CA12CA1 | |
| Valdecoxib SCHEMBL5998054 | 0.86 | PTGS2 (0.88) | PTGS2CA2CA9CA12CA1 | |
| SCHEMBL214781 | 0.86 | PTGS2 (0.66) | PTGS2CA2CA9CA12CA1 | |
| SCHEMBL6169656 | 0.85 | PTGS2 (0.59) | PTGS2CA2CA9CA12CA1 | |
| SCHEMBL8474584 | 0.85 | PTGS2 (0.59) | PTGS2CA2CA9CA12CA1 | |
| SCHEMBL6169647 | 0.83 | PTGS2 (0.60) | PTGS2CA2CA9CA12CA1 | |
| SCHEMBL8475026 | 0.83 | PTGS2 (0.60) | PTGS2CA2CA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0880362-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4 RECEPTOR ANTAGONIST | SEARLE & CO (US) | 2005-05-25 | — | — | EP | claimed |
| US-20050043355-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | claimed |
| US-20040106668-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | claimed |
| US-6617345-B1 | Cyclooxygenase-2 inhibitor is (5-bromo-2-(4-fluorophenyl )-3-(4-(methylsulfonyl)phey)-thiophene), N-(2-(cyclohexyloxy 4-nitrophenyl)-methanesulfonamide), meloxicam, flosulide or cyclic substituted phenyl sulfones or sulfonamides | G.D. SEARLE & CO. | 2003-09-09 | — | — | US | claimed |
| US-20030004191-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | PHARMACIA CORPORATION | 2003-01-02 | — | — | US | claimed |
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | G.D. SEARLE & CO. | 2002-10-03 | — | — | US | claimed |
| EP-0880363-B1 | COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2002-09-11 | — | — | EP | claimed |
| US-20020107276-A1 | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist | PHARMACIA CORPORATION | 2002-08-08 | — | — | US | claimed |
| US-6376528-B1 | SYNERGISTIC MIXTURE | G. D. SEARLE & CO. | 2002-04-23 | — | — | US | claimed |
| US-6342510-B1 | ANTIINFLAMMATORY AGENTS AND ENZYME INHIBITORS | G. D. SEARLE & CO. | 2002-01-29 | — | — | US | claimed |
| EP-0888127-B1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2001-12-12 | — | — | EP | claimed |
| EP-0888127-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | claimed |
| EP-0880362-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4 RECEPTOR ANTAGONIST | G.D. SEARLE & CO. (US) | 1998-12-02 | — | — | EP | claimed |
| EP-0880363-A1 | COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-12-02 | — | — | EP | claimed |
| WO-1997029776-A1 | COMBINATIONS HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING CYCLOOXYGENASE-2-INHIBITORS AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1997029775-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| WO-1997029774-A1 | COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1997-08-21 | — | — | WO | claimed |
| US-7141599-B2 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin | PHARMACIA CORPORATION (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1027048-A2 | SELECTIVE CYCLOOXYGENASE-2 INHIBITORS AGAINST PREMATURE LABOR | G.D. SEARLE & CO. (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999022720-A2 | SELECTIVE CYCLOOXYGENASE-2 INHIBITORS AGAINST PREMATURE LABOR | G.D. SEARLE & CO. (US) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107276-A1 | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist | LTB4R2, LTB4R, CYSLTR2 | PTGS2 13/4885CA2 3499/4885CA9 4420/4885 |
| US-20040106668-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin | LTB4R2, LTB4R, CYSLTR2 | PTGS2 9/4885CA2 1832/4885CA9 4229/4885 |
| US-20050043355-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | LTA4H, LTB4R2, LTB4R | PTGS2 9/4885CA2 2320/4885CA9 3321/4885 |
| US-20030004191-A1 | Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor | LTA4H, LTB4R2, LTC4S | PTGS2 9/4885CA2 2299/4885CA9 3447/4885 |
| US-20020143033-A1 | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor | ALOX5, ALOX15B, ALOX15 | PTGS2 6/4885CA2 3209/4885CA9 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.